May 15, 2018 / 12:24 PM / 7 days ago

BRIEF-Rexahn Says Phase 2a Trial Of Treatment For Type Of Pancreatic Cancer Advances To Second Stage

May 15 (Reuters) - Rexahn Pharmaceuticals Inc:

* REXAHN PHASE 2A COMBINATION STUDY OF RX-3117 AND ABRAXANE® IN FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS ADVANCES TO SECOND STAGE

* REXAHN PHARMACEUTICALS INC - SMC HAS CONFIRMED THAT COMBINATION OF RX-3117 AND ABRAXANE IS SAFE AND WELL TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below